Sry Octreotde, a somastain analoue, has been shown to inhibit the growth of strointestinal cancrs n vro and in vio. To al., 1982; Hudd et al., 1989; Townsend et al., 1989) . The mehanism of action is not well known but is probably mediated by speific hormone receptors present in normal and tumour cells; thus there have been efforts to develop receptor antagonists as anti-cancer agents (Chang et al., 1986; Singh et al., 1986) .
Gastrointestinal tumours are one of the commonest causes of cancer deaths in Westen countries. Few patients present an early state of disease and the treatment of advanced gastrointestinal tumours is far from satisfactory. The contribution of cytotoxic chemotherapy has been modest and limited to palliation (Ahlgren and MacDonald, 1992) . Therefore, if a non-toxic and safe drug is found that can slow the growth of tumour, it could represent an advantage in the managemet of diseases which are difficult to treat effectively. One of the areas under investigation is the role of gastrointestinal hormones in the growth of tumours arising from the gastrointestinal tract. In fact, peptide hormones, such as gastrin and cholecystokinin have been shown to promote the growth and differentiation of normal as well as malignant gastrointestinal cells in vitro and in vivo (Kobory et al., 1982; Hudd et al., 1989; Townsend et al., 1989) . The mehanism of action is not well known but is probably mediated by speific hormone receptors present in normal and tumour cells; thus there have been efforts to develop receptor antagonists as anti-cancer agents (Chang et al., 1986; Singh et al., 1986) .
One of the most important naturally occurring antiproliferative hormones is somatostatin. It has been shown to inhibit cellular proliferation in normal and neoplastic mucosa of stomach, pancreas and colon-rectum (Reichin, 1983) .
However, the short half-life of native somatostatin and the need for its intravenous administration makes long-term somatostatin therapy impactical (Sheppard et al., 1979) .
Octreotide, a synthetic somatostatin analogue, differs from natural somatostatin, which has a half-life of [1] [2] [3] in that it has higher potency and a much longer half-life (Bauer et al., 1982) .
While it is now considered an accepted treatment for neuroendocrine tumours of the gut, such as carcinoids, insulinomas and VIPomas, it is still unclear whther octreotide is effective against non-endocrine gastrointinal tumours (Kraenzlin et al., 1985; Boden et al., 1986; Kvols et al., 1987; Saltz et al., 1993) .
In fact, although experimental evidence for antiproliferative activity has been shown for octreotide in gastric, pancreatic and colorectal cancers, initial clinical trials gave confliing results (Savage et al., 1987; Klijn et al., 1990 Every 2 weeks, patients of both arms were looked after in the same setting and by the same physicn and nursing staff in order to record both side-effects of treatment with octreotide and possible complications related to the neoplastic disease.
Tumour measurements were obtained at entry into the study and every 8 weeks. Responses were evaluated using the criteria of Miller et al. (1981) . Patients in both arms were followed until death.
The study was designed as a randomised tial in which at least 50 patients were to be assigned to each of the two treatment arms. The sample size was determined in order to detect a 30% difference in absolute increase in survival between the two treatment groups, with alpha and beta error of 0.05 and 0.1 respectively. A benefit in survival of at least 30% was thought to have a positive clnical impact considering both the poor survival time of advanced gastrointestinal cancer patients refractory to chemotherapy and the aspects related to the economic cost and compliance of the octreotide treatment.
Randomisation using cards from a computer-generated list in sealed envelopes was performed by a person not involved with the care or evaluation of the patients. The primary outcome variable in this study was the survival length. Outcome variable of secondary importance was response rate. Survival was calulated from the date of randomisation using the Kaplan-Meier estimates. The log-rank test was used to assess the difference between survival curves.
The chi-square test was used to analyse the statistical (Glantz, 1992) .
Resut
Patients Between January 1990 and December 1992, 107 patients with advanced gastrointestinal carcinoma were included in the study. Patient characteristics are summarised in Table I . Fifty-five patients received octreotide and 52 the best supportive care only. In the octreotide arm primary tumours were: stomach 15, pancreas 16, colon-rectum 24; in the control group, stomach 14, pancreas 16, colon-rectum 22. Previously chemotherapeutic regimens were: for gastric cancer a weekly adminisation of 5-fluorouracil (5-FU), 6S-leucovorin, cisplatin and epidoxorubicin; for pancreatic cancer a weekly administration of 5FU, leucovorin and interferon alpha-2b 3 MU three times a week; for colorectal cancer a 5 day schedule of 5FU, leucovorin and interferon alpha-2b, with cycles repeated every 3 weeks.
Median time to progression from onset of chemotherapy was 6 months in the octreotide arm and 5 months in the control group (Table I ). In the octreotide arm 12 patients responded to previous chemotherapy vs 13 in the control group. Both arms were well balanced also for other possible prognostic factors, such as performance status, liver function tests and sites of metastases. (Figures 1-4) .
Twenty-two patients (40%) treated with octreotide showed relief of pain, with concomitant discontinuation in analgesc treatment requirements. Downward et al., 1984) . Consequently, somatostatin could be of value for impding the growth of cners, such as gastric, pancreatic and colorectal, in which gastrointestinal hormones as well as growth factors might be involved (Schally et al., 1987) . However, the half-life of somatostatin in plasma (estimated to be 1.1-3.0 min in humans) presents difficulties for its clinical use (Sheppard et al., 1979 Townsend et al., 1987; Schally, 1988 These conflicting results probably rflect the difficulty in assssing the activity of an agent such as ocuotide and the lack of knowledge of its proper dose and scheme of administration. In fact, apart from the study of Krook et al. (1993) , previous pilot stude were performed to evaluate the clinicl activity of octreotide in terms of objective responses (Savage et al., 1987; Klijn et al., 1990; Smith et al., 1992) . However, it is possible that tratment with octreotide or other similar agents could be valuable if it consistetly results in stabilisation of disease, and if this is associated with an improvement in survival.
A second problem arisng from the studies cited above is the octreotide dose, which was probably too low to achieve an anti-tumour effect. In fact, experimental data suggest that a serum octreotide level of about 1200ngml[', which is equivalent to 1.2 x 10'6 M, appears to be effective (Dy et al., 1992) . This concentration can be achieved clinicly after a subcutaneous injection of at least 200 pg of octreotide repeated every 8 h. (Del Pozo et al., 1988) . On the contrary, octreotide was generally adminired at a dose of 200 pg twice daily or 100-150 pg thrice daily, this corresponds to 60-75% of the optimal dose as judged from pharmacokinetic models (Del Pozo et al., 1986; Dy et al., 1992) .
Another critical point in previous studies could be the administration of octreotide for a long time without discontinuation. Preclinical data have revealed that after continuous administration of octreotide desensitisation or tachyphylaxis of its inhibitory effect on receptors and plasma growth hormone, insulin and IGF-I concentrations develops within 6-10 days, but this could be reduced if 'drug-free' days were inserted in the protocol (Redding and Schally, 1983; Lamberts et al., 1987 
